Sermorelin vs CJC-1295 vs Ipamorelin: what TikTok gets wrong

What did @livv.peptides actually say?

Here's the awkward truth: the transcript from this video is not about peptides at all. The audio captured is song lyrics, something along the lines of "every day and night, I got you on my mind" repeated on loop. There are no spoken claims about sermorelin, CJC-1295, ipamorelin, or tesamorelin in the transcript provided.

The caption, however, does make specific claims worth examining. It states that these three peptides "all stimulate GH, but timing, duration, and outcomes differ," and frames that distinction as the key to getting results. So while the video itself appears to be a music-backed visual, the written claims in the caption are what we're actually fact-checking here. That's a meaningful limitation. Claims dropped in a caption, pointing to a third-party article, carry less accountability than spoken, explained content.

Does the science back this up?

The caption's core claim, that these peptides differ in timing, duration, and outcomes, is accurate and actually undersells the complexity. These are not interchangeable drugs wearing different labels.

Sermorelin is a truncated analog of growth hormone-releasing hormone (GHRH), with a short half-life of roughly 10-20 minutes. It stimulates the pituitary in a pulse that mimics natural GH secretion, which is part of why some clinicians prefer it for physiological dosing strategies. CJC-1295, particularly the DAC (Drug Affinity Complex) version, binds to albumin and extends its half-life to days rather than minutes, producing sustained GH elevation rather than discrete pulses. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that works on ghrelin receptors and is often combined with CJC-1295 to produce a synergistic GH release. Tesamorelin is a stabilized GHRH analog approved by the FDA specifically for HIV-associated lipodystrophy, studied in randomized controlled trials (Falutz et al., 2010, New England Journal of Medicine). These are mechanistically distinct compounds. Saying they "all stimulate GH" is like saying aspirin and morphine both reduce pain.

What did they get wrong (or right)?

Credit where it's due: the caption gets the basic pharmacological framing right. These peptides do differ meaningfully in timing and duration, and that distinction does matter clinically. Collapsing them into one category, "growth hormone peptides," is a pet peeve of anyone who has read the actual pharmacokinetic literature.

What's missing is more concerning. The caption implies that knowing these differences is what separates people who get results from people who don't. That's a sales framing, not a clinical one. There is no robust long-term safety data for off-label use of CJC-1295 or ipamorelin in healthy adults. A 2019 review in Endocrine Practice noted that GH secretagogue use outside of approved indications lacks controlled trial evidence for safety and efficacy. The FDA does not approve these peptides for general wellness, body composition, or anti-aging. Tesamorelin (brand name Egrifta) has a specific, narrow indication. Compounded versions of any of these are not equivalent to studied pharmaceutical-grade compounds, and the regulatory environment around compounded peptides has tightened considerably since 2023.

What should you actually know?

If you're considering any of these compounds, the mechanism differences are real and worth understanding, but they don't answer the more important questions: are they safe for you specifically, are they legal in your jurisdiction, and is the source you're using producing something that actually matches what's on the label?

Sermorelin has the longest history of clinical use and the most conservative safety profile in the GH-stimulating peptide category. CJC-1295 with DAC produces a "GH bleed" effect that some endocrinologists consider less physiologically appropriate than pulsatile release. Ipamorelin's selectivity, meaning it doesn't significantly raise cortisol or prolactin the way older GHRPs do, is genuinely a point in its favor based on animal and small human studies. Tesamorelin should not be discussed in the same breath as the others for wellness purposes. It is an FDA-approved drug with a specific patient population, studied in HIV-positive individuals with abdominal fat accumulation. Treating it as a general body composition option misrepresents the evidence base.

None of these compounds should be self-prescribed, purchased from unregulated suppliers, or used without physician oversight and baseline labs. The caption's framing, that "knowing the difference is where results start," skips over the more pressing first step: knowing whether using these at all is appropriate for your situation.